Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort

This study is tracking people with neuroendocrine tumors of the gut or pancreas (GEP-NETs) who are being treated with a type of targeted radiation therapy called PRRT (peptide receptor radionuclide therapy). Researchers want to better understand how these tumors respond to treatment over time using multiple types of imaging and testing. **You may be eligible if...** - You are 18 or older - You have been diagnosed with an inoperable GEP-NET that is spreading or growing - Your tumor has a specific protein marker (somatostatin receptor positive) confirmed by a special scan - Your doctor has recommended PRRT as your treatment - You are in reasonably good general health (Karnofsky score ≥60) - Your expected survival is more than 6 months **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have a known allergy to the treatment materials (including Lutetium-177 or amino acid solutions) - You cannot have an MRI scan - You received extensive radiation to liver tumors in the past 12 weeks - You have uncontrolled brain metastases - Your heart, bone marrow, liver, or kidney function does not meet minimum requirements - You have previously received PRRT treatment Talk to your doctor to see if this trial is right for you.